AACR 2026 现场信号· @ · X·· 2026-04-21评分60
正文 · 原文
Novel pan-RAF/MEK molecular glue NST-628 shows promise at #AACR26:
38% ORR & 85% DCR in pretreated NRAS/BRAF class II/III melanoma
Demonstrates CNS activity
Manageable safety profile (predominantly G1-2 AEs)
https://t.co/YuZle4FAHu
热度 1 · 1 赞 · 0 回复 · 0 转发
会议摘要
CT129按 代号 NST-628 对上
Preliminary results from a Phase 1a/b dose-escalation and expansion trial of the pan-RAF-MEK molecular glue NST-628 in patients (pts) with advanced or refractory RAF, KRAS, and NRAS-mutant solid tumorsAhmad A. Tarhini, Monica Chen, Jia Liu, Varun Monga, Victoria Atkinson, Sarina A. Piha-Paul, Bartosz Chmielowski, Benjamin Herzberg, Charlotte Lemech, Prachi Bhave, Ganessan Kichenadasse, Gerald Falchook, Janice Mehnert, Andrae Vandross, Mohamad Salkeni, Meredith McKean, David Wages, Ann Marie Kennedy, Meagan B. Ryan, John Clark, Abdulaziz Nanah, Michael J. Fossler, Philip Komarnitsky, Igor Puzanov
读摘要原文 →来源：AACR 2026 现场信号 · x.com